REMDESIVIR- NO BENEFIT IN REDUCTION OF COVID-19 DEATHS World Health Organization (WHO) published a non-peer-reviewed preprint study on MedRxiv  on October 15, 2020 showing that Remdesivir barely reduces the mortality rate of COVID-19 patients. The study is a result of the so-called 'SOLIDARITY Trial' in which the data of 11,266 patients was evaluated.  Gilead Sciences in a statement  argued that by having the study published as a preprint, "the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion." This trial studied re - purposed anti- viral drugs - Remdesivir, lopinavir and others like Interferon beta - 1A,and HCQS found that none of these helped reduce COVID-19 deaths The trial held from March 22 to October 4 - 2020 followed 11, 266 patients across 30 countries in all WHO six regions . These drug regimens appeared to have little or no effect on hospitalized COVID-19 patients as indicated by overall mortality, Initiation of ventilation and duration of hospital stay No study drug appreciably reduced initiation of ventilation in those not already ventilated This was one of the world 's largest trial on Remdesivir and three other re - purposed drugs Of the 2743 patients- who were given Remdesivir along with other treatment '- 301 died and in control group of 2708 patients who were,given other treatments , 303 died . So , there was no impact on mortality reduction However , - US based Gilead Sciences - the makers of Remdesivir- said , The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies, Published in peer - reviewed journals validating the clinical benefits of Remdesivir



In my opinion- which may be wrong - Remdesivir will be effective for mild to moderate cases of COVID-19 disease-,where anti - viral activity of Remdesivir is not affected by other factors like cytokine storm, thromboembolism, septicaemia etc. In severe cases- where mortality is high - Remdesivir may not affect the mortality rates . At least in india - where ICU care - may not be at par with western countries- Remdesivir in critically ill cases may not alter the prognosis. But this is a trial from March to October- and it cannot be dismissed US based Gilead Sciences- the makers of Remdesivir- may not like this study Thanks

Clinically no body know ,what to do and when to do ,WHO regularly and routinely changing its position by passing direction. Due to pneumonia pt require ventilatory support to avoid further complications antiviral drugs may reduce mortality but other symptoms will be treated accordingly. Actually we are fighting corona pandemic as unskilled force. Everyone has a new idea to tackle this red dragon one day and next day it prove useless.

Thank you doctor

View 1 other reply

Pts who require ventilatory support have complications due to thrombotic events & hyper immune response which is unlikely to be influenced by antiviral drugs & hence mortality may not be affected at this stage but pts with mild to moderate symptoms will definitely be benefited & long term statistics may change

I agree

Medicine is evidanced based medicine and clinical study over huge no of pt with no conclusive result definately have some meaning.These drugs have little effct on mortality issue in covid 19 hospitalised pt have great importance.

Thank you doctor


Diseases Related to Discussion

Cases that would interest you